Diagnosing clinical progressive supranuclear palsy (PSP) is challenging. We hypothesize that there are more cases of pathological PSP than have been clinically identified, but its diagnosis is challenging because the initial lesions and progression of PSP have not yet been clarified. The purpose of our study was to clarify the incidence of PSP in consecutive autopsy cases and identify pathological characteristics of early PSP. We investigated 324 consecutive autopsy patients from a general geriatric hospital (age, mean±SD=82.5±8.7 years). Paraffin sections of the midbrain were immunostained with anti 4-repeat tau antibodies (RD4). We selected cases showing RD4-positive neurofibrillary tangles and tufted astrocytes in the midbrain sections. Then, we used anti-phosphorylated tau antibody to immunostain sections from the basal ganglia, subthalamic nucleus, midbrain, pons, medulla, and cerebellum. Of the 324 patients, 35 had RD4-positive structures in the midbrain. From these 35 cases, we excluded those for which autopsies confirmed definite PSP (n=5) and cases of corticobasal degeneration (n=1), Alzheimer's disease (n=11), dementia of grain (n=10), and neurofibrillary tangles predominant forms of senile dementia (n=2), leaving 8 cases. We diagnosed these 8 cases as pure PSP-type tauopathy.
Introduction
Progressive supranuclear palsy (PSP) was first described as a distinct disorder from Parkinson's disease (PD) in corticobasal syndrome 5 , progressive non-fluent aphasia 6 , PSP with primary lateral sclerosis 7 , and PSP with cerebellar ataxia 8 . This variability in clinical phenotypes created challenges in diagnosing PSP.
Daniel SE et al. reported seventeen cases of pathologically confirmed PSP. Of the seventeen autopsy-proven PSP cases, only 7 cases were diagnosed clinically as PSP, and the remaining 10 cases were not diagnosed as PSP clinically because of their lack of ophthalmoplegia. The average age at death was higher for the patients with pathological PSP without opthalmoplegia than for those with opthalmoplegia 9 . This finding emphasizes the fact that diagnosis of clinical PSP is particularly difficult in elderly patients.
We previously reported 9 cases of diagnosed neuropathological PSP among 1,241 consecutive autopsy cases 10 , which represents a prevalence of 0.7% for our study sample. This was much higher prevalence than those reported by previous studies, which indicated expected rates of 1 5 cases per 100,000 people in the general population, based upon community epidemiological studies 11, 12 .
The pathological process of neurodegenerative diseases is thought to begin many years before diagnosis, with clinical symptoms presenting when the rate of disease progression exceeds a threshold. This preclinical phase of disease progression is hypothesized to provide an opportunity for therapeutic intervention. There have been many reports on preclinical Alzheimer's disease (AD) and preclinical Parkinson's disease (PD) 13, 14 . We previously reported 58 cases of PD with dementia (PDD) and dementia with Lewy bodies (DLB) in a sample of 1,241 consecutive autopsy cases, from which 196 cases had alpha synuclein-positive structures, but did not fulfill the diagnostic criteria 10 . These cases may represent preclinical PD, PDD, and DLB. We hypothesize that there are a considerable number of preclinical PSP cases, similar to preclinical AD and PD. However, few neuropathological reports on patients at the preclinical stage of PSP are found in the literature 15 .
In the present study, we conducted immunohistochemical analyses on brain tissue from a series of autopsied patients. We performed a midbrain screening test for all consecutive autopsy cases and then compared immunostaining for tau pathologies with anti 3-repeat tau (RD3) and anti 4-repeat tau (RD4) antibodies. The pathological finding of RD4-positive and RD3-negative neurofibrillary tangles (NFTs), pretangles, and tufted astrocytes in the midbrain was classified as PSP-type tauopathy. The purpose of this study was to describe the incidence of PSP-type tauopathy at autopsy and investigate propagation of this tauopathy.
Materials and Methods

Tissue Source
Brains and spinal cords were obtained from 340 con- 
Case Selection for PSP-type Tauopathy
Midbrain sections from consecutive autopsy cases were directly fixed in 4% paraformaldehyde for 48 hours 31 .
Then, the blocks of midbrain tissue were stained by Immunohistochemistry with RD4 and RD3. We selected the cases having RD4-positive and RD3-negative NFTs and/ or pretangles and RD4-positive and RD3-negative tufted astrocytes in the midbrain. Tufted astrocytes were detected as aggregates of fine tau-positive fibers with a concentric arrangement of tree-shaped branching 32 . Next, we used AT8 to immunostain sections of the basal ganglia, subthalamic nucleus, midbrain, pons, medulla, and cerebellum from the selected cases. These sections were fixed in 20% buffered formalin. At a magnification of 100 ,
we counted the number of NFTs, pretangles, and tufted astrocytes with AT8 immunohistochemistry in the putamen, globus pallidus, subthalamic nucleus, substantia nigra, oculomotor nucleus, pontine nucleus, inferior olive nucleus, and dentate nucleus. Samples were classified according to the following grading system: Grade 0, AT8-positive structures were not observed; Grade 1, 1 3 AT8-positive structures were observed; Grade 2, 4 9 AT8-positive structures were observed; Grade 3, more than 9 AT8-positive structures were observed (Fig. 1) .
Results
Neuropathological Diagnoses
Neuropathological diagnoses included AD (n=49); DG (n=20); NFTD (n=18); PD, PDD, and DLB (n=9); PSP (n= 3); spinocerebellar degeneration (n=3); motor neuron disease (n=2); multiple system atrophy (n=2), CBD (n=1);
and frontotemporal lobar degeneration (n=1). Comorbid pathologies included AD with DLB (n=11), AD with DG (n=7), DG with NFTD (n=6), AD with PSP (n=1), PDD with PSP (n=1), AD with motor neuron disease (n=1).
The remaining patients did not fulfill both clinical and pathological criteria for any single neurodegenerative disease ( Table 1) .
PSP-type Tauopathy
Thirty-five of the 324 patients had RD4-positive struc- There were few AT8-positive tufted astrocytes outside of these described regions.
We compared PSP-type tauopathy (n=8) without other tauopathy ( Table 2) , PSP-type tauopathy complicated by AD (n=10), and PSP-type tauopathy complicated by DG A. Nogami, et al Fig. 1 Semi-quantitative evaluation of tau-positive structures. The number of tau-positive NFTs, pretangles, and Tufted astrocyte were classified into the following grades: Grade 0, AT8-positive structures were not observed; Grade 1, 1 3 AT8-positive structures were observed; Grade 2, 4 9 AT8-positive structures were observed; Grade 3, more than 9 AT8-positive structures were observed. NFT, neurofibrillary tangle; PT, pretangle; TA, tufted astrocyte. Scale bar=100 μm From these 29 cases, we excluded those for which 
Clinical Data of Pure PSP-type Tauopathy
One patient had dementia and Parkinsonism. One patient had mild dementia. There were no patients with vertical opthalmoplegia ( Table 2) . There is no correlation between the distribution of gliosis and that of tufted astrocyte 36 , indicating that Tufted astrocyte may not be directly involved in the progression of PSP-type tauopathy.
Discussion
In cases with PSP-type tauopathy, NFTs were observed more frequently than Tufted astrocyte, using the AT8 immunostain. However the density of NFTs and pretangles, and that of ATs, were equal using the RD4 immunostain. 37, 38 . In the present study, most cases exhibited NFTs and pretangles in the substantia nigra, globus pallidus, and subthalamic nucleus. In the previous reports of early stage PSP cases, tau-positive NFTs and pretangles were not described in the dentate nucleus, putamen, and oculomotor nucleus. However, in the present study, NFTs and pretangles were observed not only in the substantia nigra, globus pallidus, and subthalamic nucleus, but also in the dentate nucleus, putamen, and oculomotor nucleus. These results suggest that NFTs may occur in the dentate nucleus, putamen, and oculomotor nucleus before they begin to occur in the globus pallidus and subthalamic nucleus. We found that PSP-type tauopathy af- Our present results indicated that a unique and definite process of neurodegeneration does not exist for PSPtype tauopathy. However, NFTs were observed in the substantia nigra in all cases with PSP-type tauopathy, indicating that PSP-type tauopathy may begin with NFTs in the substantia nigra.
We found some cases with PSP-type tauopathy in this study. We assumed they might be preclinical PSP cases which was similar in nature to preclinical AD and PD.
However, PSP-type tauopathy might be a part of nonspecific pathological changes related to aging.
We found a few cases compatible with early stage PSP in our sample of hundreds of consecutive autopsy cases.
Our novel neuropathological findings are unique and have not been reported thus far. To elucidate the cause and pathological mechanisms of PSP, this new classification, which we have termed PSP-type tauopathy, should be investigated biochemically and molecular genetically further.
